StockNews.com Begins Coverage on Curis (NASDAQ:CRIS)

Equities research analysts at StockNews.com assumed coverage on shares of Curis (NASDAQ:CRIS) in a research report issued to clients and investors on Friday. The firm set a “hold” rating on the biotechnology company’s stock.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price target on shares of Curis in a report on Tuesday, December 10th.

Curis Stock Performance

CRIS stock opened at $2.66 on Friday. The company’s 50 day moving average price is $3.12 and its 200 day moving average price is $3.98. Curis has a fifty-two week low of $2.57 and a fifty-two week high of $17.49. The firm has a market capitalization of $22.52 million, a price-to-earnings ratio of -0.34 and a beta of 3.49.

Institutional Investors Weigh In On Curis

Several hedge funds have recently modified their holdings of the stock. Squarepoint Ops LLC acquired a new stake in shares of Curis during the fourth quarter worth $35,000. Millennium Management LLC lifted its holdings in shares of Curis by 92.6% during the fourth quarter. Millennium Management LLC now owns 25,557 shares of the biotechnology company’s stock worth $78,000 after purchasing an additional 12,287 shares during the period. Bleichroeder LP lifted its holdings in shares of Curis by 1,982.2% during the fourth quarter. Bleichroeder LP now owns 520,539 shares of the biotechnology company’s stock worth $1,593,000 after purchasing an additional 495,540 shares during the period. Alyeska Investment Group L.P. acquired a new stake in shares of Curis during the fourth quarter worth $607,000. Finally, Samsara BioCapital LLC acquired a new stake in shares of Curis during the fourth quarter worth $607,000. 29.97% of the stock is owned by institutional investors and hedge funds.

Curis Company Profile

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.